Sector Update: Healthcare; Tekmira's TKM-Ebola Clinical Study Put on Hold by U.S. FDA Pending Additional Data


Shutterstock photo

Healthcare stocks were mixed in afternoon trading. The S&P/TSX Healthcare index was down 0.3%.

Tekmira Pharmaceuticals (TKM.TO): -17.2%

Valeant Pharmaceuticals (VRX.TO): -0.4%

Catamaran (CCT.TO): +0.04%

Oncolytics Biotech (ONC.TO): +2.8%

Cardiome Pharma (COM.TO): -2.2%

In corporate news, Tekmira Pharmaceuticals said it has been advised by the U.S. FDA that the TKM-Ebola Phase I healthy volunteer clinical study has been placed on clinical hold. The dual-listed biopharmaceutical company said the study has been put on hold, pending additional data related to the mechanism of cytokine release, observed at higher doses, to ensure the safety of healthy volunteer subjects. The study is assessing the safety, tolerability and pharmacokinetics of administering TKM-Ebola to healthy adult volunteers without administering any steroid pre-medications.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2014 All rights reserved. Unauthorized reproduction is strictly prohibited.

This article appears in: Investing , Commodities

More from MT Newswires


MT Newswires

MT Newswires

Market News, Commodities
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by